CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in CNS Pharmaceuticals, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- 0 vs. Q2 2023
- Shares held
- 116.7K
- +11.9K (+11.4%) vs. Q2 2023
- Total value
- $131.7K
- −$102.8K (−43.8%) vs. Q2 2023
- New holders
- 2
- 4 more added
- Sold out
- 2
- 1 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CNSP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $1.34M |
| Q1 2026 | 12 | $348.7K |
| Q4 2025 | 10 | $652.4K |
| Q3 2025 | 8 | $221.5K |
| Q2 2025 | 11 | $421.8K |
| Q1 2025 | 7 | $55.2K |
| Q4 2024 | 21 | $297.3K |
| Q3 2024 | 14 | $75.3K |
| Q2 2024 | 10 | $227.8K |
| Q1 2024 | 19 | $351.0K |
| Q4 2023 | 16 | $425.3K |
| Q3 2023 | 12 | $131.7K |
| Q2 2023 | 12 | $234.4K |
| Q1 2023 | 13 | $190.5K |
| Q4 2022 | 10 | $335.0K |
| Q3 2022 | 21 | $232.0K |
| Q2 2022 | 23 | $343.5K |
| Q1 2022 | 20 | $589.0K |
| Q4 2021 | 24 | $828.0K |
| Q3 2021 | 20 | $1.44M |
| Q2 2021 | 20 | $2.64M |
| Q1 2021 | 19 | $3.04M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding CNS Pharmaceuticals, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Plante Moran Financial Advisors, LLC | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 7 | $8 | 0.00% | 00.0% | Unchanged |
| Global Retirement Partners, LLC | 53 | $57 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 55 | $63 | 0.00% | −1,071−95.1% | Reduced |
| Morgan Stanley | 67 | $76 | 0.00% | +67 | New |
| Wells Fargo & Company | 505 | $576 | 0.00% | +2+0.4% | Added |
| Tower Research Capital LLC (TRC) | 4,740 | $5.40K | 0.00% | +2,766+140.1% | Added |
| FSM Wealth Advisors, LLC | 19,084 | $21.8K | 0.01% | +2,750+16.8% | Added |
| Susquehanna International Group, LLP | 21,428 | $24.0K | 0.00% | +21,428 | New |
| State Street Corp | 22,556 | $25.3K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 23,765 | $27.1K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 24,436 | $27.4K | 0.00% | +8,294+51.4% | Added |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −22,292−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −42−100.0% | Sold out |